Fatty Liver Disease (MASLD)
Fatty liver disease refers to a buildup of excess fat in the liver. When this occurs in people who drink little to no alcohol, it was historically called NAFLD (Non-Alcoholic Fatty Liver Disease). Recently, experts have introduced a new name: MASLD (Metabolic dysfunction-Associated Steatotic Liver Disease), to emphasize its link with metabolic factors. In MASLD, fat accumulates in liver cells often due to obesity, insulin resistance, diabetes, and related metabolic issues. It is now the most common cause of chronic liver disease globally, affecting roughly a quarter of the world’s population. Fatty liver by itself often causes no symptoms, but it can progress in some people to liver inflammation (steatohepatitis), fibrosis, cirrhosis, and even liver cancer over time.
(For simplicity, we will use MASLD to refer to this condition, in line with the newer terminology, but many doctors and patients may still know it as NAFLD.)
Symptoms
In the early stages, fatty liver disease (MASLD) usually has no noticeable symptoms. Most people feel entirely normal and are often surprised to learn they have a fatty liver from an ultrasound or blood test done for another reason. Some nonspecific symptoms that a minority of patients report include:
As MASLD progresses to the stage of inflammation (called MASH – Metabolic dysfunction-Associated SteatoHepatitis, formerly NASH), some people may start developing more overt signs:
Often, MASLD is suspected because of elevated liver enzymes on a blood test (ALT, AST) or an ultrasound finding of a “bright” fatty liver. Without screening or incidental findings, many would not know they have it.
Causes
MASLD is fundamentally associated with metabolic dysfunction. Key factors and causes include:
In summary, MASLD is not caused by a virus or a single agent, but rather by a combination of lifestyle and genetic factors that lead to fat build-up in the liver. It often coexists with obesity and diabetes.
Diagnosis
Diagnosis of fatty liver (MASLD) often starts with incidentally noted abnormal tests:
A newer concept is the acronym MAFLD (Metabolic Associated Fatty Liver Disease) which has diagnostic criteria focusing on evidence of fatty liver plus metabolic risk factors. Regardless of terminology, if imaging shows fat in the liver and the person has metabolic risk factors (obesity, diabetes) and no significant alcohol use, the diagnosis of MASLD is made.
An important part of evaluation is determining if the person has just fatty liver (steatosis) or has progressed to steatohepatitis (fat plus liver cell injury and inflammation). Blood tests and scoring systems (like the NAFLD fibrosis score, FIB-4, etc.) or FibroScan can help identify those with advanced fibrosis who need more aggressive intervention or specialist referral.
Treatment
There is currently no single magic-pill medication specifically approved to cure MASLD. However, the condition can often be reversed or improved with lifestyle changes. Key aspects of management include:
Medications: While none are officially approved specifically for NAFLD/NASH yet, some are used in certain situations:
In patients who progress to cirrhosis from MASLD (sometimes called metabolic-associated steatohepatitis cirrhosis), management includes all the above plus monitoring for complications. Liver transplantation is an option for end-stage liver disease or liver cancer resulting from MASLD – and indeed, NASH cirrhosis is now one of the leading indications for liver transplant in Western countries.